Pediatric pancreatic Burkitt lymphoma with obstructive jaundice: case report of a six-year-old child

Imane Athmani¹, Marie-Amelyne Le Rouzic¹, Julie Valduga¹, Ludovic Mansuy¹, Audrey Contet¹, Marie-Agnès Galloy², Fanny Fouyssac¹, Pascal Chastagner*¹

¹Department of Pediatric Hematology and Oncology, Children’s University Hospital, Nancy, France, ²Department of Pediatric Radiology, Children’s University Hospital, Nancy, France

Abstract

Introduction: Burkitt lymphoma represents about 50% of non-Hodgkin lymphomas and 3% of cancers in children. It commonly affects the abdomen; however, pancreatitis is a very rare initial presentation. Less than 10 cases with this presentation are reported in the literature. Observation: We report the case of a six-year-old girl who presented a rapidly progressing obstructive jaundice evolving for a week. The LDH rate was not increased. Medical imaging has shown a global increase in the size of the pancreas, homogeneous hepatomegaly with dilatation of the gallbladder and the intra-hepatic bile ducts, and infiltration of the left ovary, without ascites. The patient was diagnosed with pancreatic Burkitt Lymphoma after an endoscopic exploration and tumor biopsy. Conclusion: While extremely rare, Burkitt lymphoma should be evoked in the case of pancreatitis with a global increase of the pancreas size, associated with other intra-abdominal organ infiltration in the pediatric population.

Keywords: Burkitt lymphoma, pancreatic tumor, obstructive jaundice, children, chemotherapy

Introduction

Burkitt lymphoma is a high grade B-cell non-Hodgkin lymphoma which often presents with extranodal manifestations and occurs most often in children and immunocompromised hosts. It is one of the fastest growing malignancies in humans. The sporadic form commonly affects the abdomen, and the ileocecal region is the main site of involvement [1-4]. The frequency of pancreatic Burkitt lymphoma among lymphoma of the abdomen is not known because of its rarity. Primary pancreatic lymphoma represents less than 0.5% of all pancreatic masses in adults. Moreover, acute pancreatitis is a very rare initial presentation of non-Hodgkin lymphomas [5-10]. We present the case of a six-year-old girl diagnosed with Burkitt lymphoma who presented with obstructive jaundice and pancreatitis.

Case Report

We report the case of a six-year-old female child who presented with jaundice evolving for one week and who had had abdominal pain and diarrhea for several weeks. She had no fever. The parents described a one-kilogram weight loss over a week, with good overall physical condition. The Lansky score was 100%. The patient had no personal or family medical history, no surgical history, and had never travelled abroad.

The clinical examination found isolated conjunctival icterus and reproducible pain upon palpation of the epigastric region. There was no mass, no liver or spleen enlargement.

Biological characteristics were as follows: hemoglobin: 11.7 g/dL, total leucocyte count: 5520/mm³, platelet count: 267 000/mm³, hepatic cytolysis with AST: 212 IU/L and ALT:
195 IU/L, lipase > 600 IU/L, total bilirubin: 162.1 µmol/L, direct bilirubin: 141.9 µmol/L, LDH: 285 IU/L, prothrombin time ratio: 0.91, TQ: 86%, fibrinogen: 4.7g/L, blood sugar level: 84 mg/dL, uric acid: 27 mg/L, creatinine: 9 mg/L, potassium: 5 mmol/L. Serological tests for EBV, CMV, HAV, HBV, HCV, VIH 1 and 2, HSV 1 and 2 were negative, as were PCR results.

Abdominal ultrasound showed a dilatation of both the extra- and intra-hepatic bile ducts. The pancreas head was shifted forward and laterally by a nodular mass measuring 34 x 33 mm. It also showed a homogenous hepatomegaly with regular outlines (145 mm), a normal-sized and homogeneous spleen and a retro-vesical elongated solid mass (70 x 30 mm) being attached to the uterus, with a thin layer of intraperitoneal effusion around this pelvic mass.

An abdominal and pelvic CT scan was performed which revealed a global enlargement of the pancreas with a pseudo-tumoral aspect. It confirmed a homogeneous hepatomegaly with dilatation of the gallbladder and the intra-hepatic bile ducts. The extra-hepatic bile duct was dilated and ended brutally in the enlarged pancreas head. The retro-uterine pelvic mass was located in front of the rectum. No bone lesion was detected.

An abdominal MRI showed a global increase in the size of the pancreas without pancreatic duct dilatation. At the back of the womb and in front of the rectum, the heterogeneous mass was measuring 75 x 53 x 37 mm (Figure 1).

Fig. 1. Sagittal (a) and axial (b, c) sections of pelvic MRI showing a retro-uterine pelvic mass located in front of the rectum and measuring 75 x 53 x 37 mm.
Endoscopic exploration revealed that the retro uterine mass was an increased-size ovary most likely due to a tumoral infiltration. There was no ascites. Tumor biopsy samples were performed during gastrointestinal endoscopy.

Histopathological examination confirmed the diagnosis of Burkitt lymphoma. The lymphoid cells expressed CD45, CD20, CD79a, C MYC, CD10, BCL6 but were negative for BCL2, CD34, CD30, MUM1. Tumor proliferative activity (Ki-67 expression) was estimated at around 100% in lymphoid cells. There was no expression of WT1, desmin, TdT, myogenin or CD99. Cytogenetic testing revealed a c-MYC gene rearrangement in 15 to 20% of tumor cells.

Moreover, a thoracic and cervical CT scan showed no lymphadenopathy. A bone marrow aspiration showed a normocellular marrow, with rare undifferentiated cells but no blast cells. A bone marrow biopsy and a cerebrospinal fluid assessment were performed and yielded normal results. The PET scan (performed after 9 days of steroids therapy) showed no suspicious uptake of $^{18}$F-FDG.

As a result of the above investigation, the patient was diagnosed with pancreatic Burkitt lymphoma associated with an infiltration of the left ovary. She was classified as stage IV of the Saint Jude system and treated in group B according to the recommendations of Inter B-NHL-Ritux 2010 protocol.

At day 7 of the induction treatment (vincristine, cyclophosphamide, steroids and intrathecal methotrexate + hydrocortisone), the patient presented a regression of conjunctival icterus and a decrease in abdominal pain. Blood tests showed nearly complete normalization of hepatic function and lipase level.

Abdominal ultrasound showed a decrease in the pancreas size (head: 4 x 21 x 31 mm; body: 14 mm; tail: 23 mm) and a decrease in the infiltration of the left ovary (41 x 27 x 18 mm). After having completed the entire chemotherapy regimen, she is in complete remission and in very good health.

**Discussion**

Non-Hodgkin lymphoma accounts for 40 to 50% of all lymphomas in children and adolescents. It represents approximately 6% of all malignancies in patients aged 0 to 19 years though Burkitt lymphoma comprises the large majority of primary pediatric gastrointestinal tract lymphomas. It is a highly aggressive non-Hodgkin B-cell lymphoma that often presents at extranodal sites.

In the pediatric population, the more frequent presentation of Burkitt lymphoma is that of a large painful and rapidly growing mass of the abdomen with ascites. Initial work-up and staging assess the possibility of kidney, testis/ovary, bone marrow and central nervous system involvement. General evaluation must be done very rapidly because of the very short tumor-doubling time of these lymphoma cells (about 25 hours), in particular evaluating the risk of tumor lysis syndrome which could lead to acute renal failure.

Burkitt lymphoma with isolated involvement of pancreas is very rare since less than 10 cases were reported in the literature [11]. It can present as diffuse enlargement of the entire pancreas gland, caused by tumor-induced pancreatitis [12]. Obstructive jaundice is also infrequent [13].

Burkitt lymphomas are highly responsive to specifically designed multi-agent chemotherapy regimens which begin with low dose of vincristine, cyclophosphamide and steroids, aiming at avoid the tumor lysis syndrome. They are followed by intensive courses including rotations of vincristine, doxorubicine, cyclophosphamide, etoposide and high dose methotrextate and cytarabine for the central nervous system prophylaxis, associated with intrathecal injections of methotrextate. It has been demonstrated that the anti-CD20 monoclonal antibody (Rituximab), when added to these regimens, still improved the prognosis.

The reported case is particular because, while clinical signs were jaundice and abdominal pain, there was no palpable abdominal mass and no ascites which are
frequent signs at diagnosis of Burkitt lymphomas. Moreover, LDH and uric acid levels were in normal range. Finally, there was an ovary infiltration which initially led to evoke a primary tumor of the ovary, such as malignant germinoma, with metastases within the pancreas.

The diagnosis confirmation was made after histological analysis of pancreas biopsy. The pelvic mass was characterized as being an infiltration of the left ovary. No biopsy was performed on it due to diagnostic uncertainties as well as to avoid spreading tumor cells in the peritoneal cavity in case it wasn't a lymphoma. Before the histopathological diagnosis was made, the patient received steroids therapy in order to decrease the tumor mass and, thus, to reduce the extrinsic compression on the bile ducts. The biopsy and the bone marrow aspiration were performed after 4 days of steroids therapy: some undifferentiated cells were seen in the bone marrow. As a consequence, the patient was classified as stage IV of the St Jude system.

Conclusion

Burkitt lymphoma should always be considered in differential diagnosis of the pancreatitis in children presenting with a solid pancreatic mass. No imaging is able to distinguish pancreatic lymphoma from other types of masses. A rapid biopsy is an accurate measure of diagnosis aiming at starting chemotherapy promptly. The prognosis is very favorable.

Conflict of interest/Funding Statement

The authors have no conflict of interest to declare.

References